Fundraising Fox
Portola Valley · Pre-Seed–Series C · 31 people tracked
Also known as LSV CAPITAL MANAGEMENT, LLC
Find your way into Lightstone Ventures
Sign up to see every warm intro you have to Lightstone Ventures
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Lightstone Ventures team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Lightstone Ventures pursues a thesis-driven life sciences strategy focused on biotech and medtech. In biotech it seeks first-in-class drugs across all modalities including small molecules, biologics, and cell and gene therapies, with emphasis on CNS, immunology and autoimmune diseases, oncology, and ophthalmology. In medtech it targets the convergence of technology, medicine, and consumer health, including personalized medicines, targeted therapeutics leveraging data analytics, and medical technologies addressing immunology, cardiovascular, neurology, and ophthalmology. The firm invests with long-term, patient capital funding companies from startup through commercialization, and partners hands-on with founders on strategy and company building rather than simply providing capital.
Source: firm website, verified Sep 29, 2026.
Team · 31 people
from the firm's website & curated & public directories
Founder mafia
5 people who came through Lightstone Ventures went on to found or lead other companies.
What they invest in
from 67 of 87 portfolio companiesHealthtech ×45Biotech ×39Medical Devices ×36AI & Machine Learning ×9Deep Tech ×9Hardware ×7Digital Health ×6Enterprise Software ×4
HQs:United States×46Ireland×3Netherlands×2Singapore×2Belgium×1Canada×1
Who they back
founder profiles across 24 portfolio companiesFounding team size:solo founder×172 founders×33 founders×24+ founders×2
What their founders studiedfrom 11 founders with field-of-study data
Engineering ×4Life Sciences ×3Chemistry ×2Economics ×2
Where their founders worked beforefrom 14 founders with career history
Stanford University ×2
Investments · 87 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 62024 · 12023 · 52022 · 22021 · 12020 · 12019 · 42018 · 12016 · 42015 · 62014 · 441 dated
ALX Oncology develops therapies for cancer treatment, operating in the biotechnology and medical technology sectors.
BiotechHealthtechMedical Devices
Corey Goodman(Chairman)inJason Lettmann(Chief Executive Officer)in
Co-investorsage1Foresite CapitalHBM Healthcare InvestmentsHBM PartnersvenBio PartnersLogos+1 more
Shoulder Innovations develops InSet® glenoid technology for shoulder joint implants that reduce the rocking horse effect and provide mechanical stability, serving patients with severe shoulder arthritis.
HardwareHealthtechMedical DevicesNorthern California, US
Robert Ball(CEO & Executive Chairman)Matthew Ahearn(Chief Operating Officer)inJeff Points(Executive Officer)inDon Running(Manager and Chief Executive Officer)Jeff Ondrla(Chief Technology Officer)David L. Blue(Chief Customer Experience Officer)in
Board seatMike Carusi· per SEC Form D
Co-investorsAlumni VenturesAPERTURE Venture PartnersArboretum VenturesGenesis Innovation GroupGlobal BrainInvest Michigan+3 more
Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.
BiotechMedical DevicesNeedham, US
Robert WeinbergRICHARD ALDRICH(Director)AMY C. CAVERS(Executive Officer)inCATHY CAREW(Executive Officer)inJONATHAN PACHTER(Executive Officer)inROB GAGNON(Executive Officer)in
Co-investorsBessemer Venture PartnersCardinal PartnersForesite CapitalLongwood FundOberland CapitalViking Global+1 more
Contego Medical develops the Neuroguard IEP System, a 3-in-1 carotid stenting device combining a carotid stent, dilation balloon, and integrated embolic protection with a 40-micron filter to reduce stroke and cognitive impairment from microembolization.
HardwareHealthtechMedical DevicesRaleigh, US
Ravish Sachar(CEO & Founder)Paul Sanders(Chief Operating Officer)
Board seatHanson S. Gifford, III· per SEC Form D
Co-investorsHatteras Venture PartnersAmzak HealthMountain Group CapitalUS Venture Partners
PsiThera is a biotechnology company using computational and physics-based methods—including quantum mechanics, molecular dynamics, machine learning, and simulation—for mechanism-driven drug design and discovery.
AI & Machine LearningBiotechDeep Tech
Co-investorsSamsara BioCapital
Vesper Medical develops a modular venous stent portfolio designed to address the anatomical challenges of the iliac and femoral veins for treating deep venous disease.
HealthtechMedical DevicesWayne, US
Bruce J. Shook(President and CEO)Monica Klos(Executive Officer)inNeil Hattangadi(Director)inPeter Schneider(Director)Mark Garcia(Director)Dennis W. Wahr(Director)
Co-investorsNew Enterprise Associates (NEA)Gilde HealthcareVensana Capital415 Capital
Allay Therapeutics develops localized pain management technology designed to deliver several weeks of post-surgical pain relief.
BiotechHealthtechMedical DevicesSan Jose, US
Adam Gridley(Executive Officer, Director)inKristen Howells(Executive Officer)inJosh Makower(Director)Tak Cheung(Director)inKarun D. Naga(Executive Officer, Director)
BoardLeighton Read(Director)
Board seatMichael A. CarusiHanson S. Gifford, III· per SEC Form D
Co-investorsArboretum VenturesNew Enterprise Associates (NEA)SGInnovateClavystBioEvonik Venture Capital GmbH
Apreo Health develops a bronchoscopic treatment for severe emphysema using a self-expanding airway scaffold designed to reduce trapped air and improve lung function.
BiotechHealthtechMedical DevicesMenlo Park, US
Karun Durgam Naga(Executive Officer, Director)
BoardHanson S. Gifford III(Director)Zack Scott(Director)inDrew Field(Director)inDennis McWilliams(Director)in
Board seatHanson S. Gifford, IIIMichael A. Carusi· per SEC Form D
Co-investorsF-Prime CapitalIntuitive VenturesNorwest Venture PartnersStar51 Capital
Cala Health develops non-invasive prescription therapies for movement disorders, starting with a treatment for hand tremor and essential tremor.
Deep TechDigital HealthHealthtechMedical DevicesSilicon Valley, US
Kate Rosenbluth, PhD(President & Chief Innovation Officer)Kate Rosenbluth(Founder)inDeanna Harshbarger(Founder)in
Board seatMichael A. Carusi· per SEC Form D
Co-investorsAlumni VenturesAscension VenturesGlobal BrainGV (Google Ventures)Lux CapitalOSF Ventures+5 more
FemTechHealthtechMedical DevicesRedwood City, US
Christopher Owens(Executive Officer, Director)Darrin Uecker(Executive Officer, Director)
BoardKen Haas(Director)Jonathan MacQuitty(Director)inDoug Fisher(Director)
Board seatMike Carusi· per SEC Form D
Co-investorsAmzak HealthBain Capital Life SciencesEndeavour VisionFemHealth VenturesKaiser Permanente VenturesKluz Ventures+6 more
Imperative Care develops medical technologies for treating stroke and other vascular diseases, aiming to address gaps across the patient care journey.
HealthtechMedical DevicesCampbell, US
Farhad Khosravi(Executive Officer, Director)Matthew Garrett(Executive Officer)inCharles Alpuche(Executive Officer)Scott Elliott(Executive Officer)in
BoardJames Rogers(Director)Stacy Enxing Seng(Director)
Board seatHenry Albert Plain, Jr.· per SEC Form D · $100M raise · filed Mar 2026
Co-investorsAscension VenturesBain Capital Life SciencesCatalio Capital Management, LPDelos CapitalFemHealth Ventures
Nuvaira develops the dNerva Lung Denervation System, a catheter-based device used in a one-time, outpatient bronchoscopic procedure that disrupts pulmonary nerve input to treat chronic obstructive pulmonary disease (COPD).
HardwareHealthtechMedical DevicesMinneapolis, US
Martin Mayse(Founder)inSteve Dimmer(Founder)inDennis Wahr(President & CEO)inLisa Flaherty(Chief Strategy Officer)inSteve Sathre(Vice President of Finance)inSteve Paidosh(Vice President of Operations)
Board seatMichael A, CarusiHenry PlainMichael A. CarusiMike CarusiHank Plain· per SEC Form D
Co-investorsWindham Capital PartnersEndeavour VisionMorgenthalerQiming Venture PartnersRichard King Mellon FoundationSplit Rock Partners+2 more
HealthtechBelmont, US
Barry Cheskin(Executive Officer, Director)S. Arieh Zak(Executive Officer)George Green(Executive Officer)
BoardDrew Schiff(Director)Lou Bock(Director)
Board seatMichael Carusi· per SEC Form D
Co-investorsAisling CapitalArcher Capital GroupArcher Venture CapitalFrazier Life SciencesJohnson & Johnson Innovation – JJDCScale Venture Partners
Reprieve Cardiovascular develops a decongestion management system that uses real-time patient data to guide and personalize diuretic therapy for fluid removal in heart failure patients.
Digital HealthHealthtechMedical DevicesMilford, US
Tony Fields(Executive Officer)Adam Bartnik(Executive Officer)inMark Pacyna(Executive Officer, Director)inJim Dillon(Executive Officer, Director)Hanson S. Gifford III(Director)Gregory W Mann(Executive Officer)
Board seatHanson S. Gifford, III· per SEC Form D
Co-investorsArboretum VenturesRex Health VenturesDeerfield Management CompanyGenesis Venture CapitalSante Ventures
Tangible Science develops contact lens solutions designed to improve comfort and durability for wearers and to provide eye care professionals with more effective treatment options.
HealthtechMedical DevicesMenlo Park, US
Karen Havenstrite(Director)inVictor McCray(Executive Officer, Director)
BoardDouglas Crawford(Director)inHanson Gifford(Director)inChip Heath(Director)Brandon Felkins(Director)
Board seatHanson S. Gifford, III· per SEC Form D · $4.6M raise · filed Nov 2016
Co-investorsMission BiocapitalShangBay Capital LLC
Twelve transforms CO2 into chemicals, fuels, and materials through carbon transformation technology.
Advanced ManufacturingCleantechClimate TechHealthtechNew MaterialsMoses Lake, US
Nicholas Flanders(Founder)inEtosha Cave(Founder)inKendra Kuhl(Founder)inAndrew Cleeland(Executive Officer, Director)in
BoardMarc-Henri Galletti(Director)Nimesh Shah(Director)
Board seatHanson S. Gifford, IIIHenry A. Plain, Jr.· per SEC Form D
Co-investorsBreakout VenturesDCVC (Data Collective)Dolby Family VenturesFifth WallAdvantage Partners Inc.Aera VC+36 more
65LAB accelerates drug discovery and therapeutic company formation by connecting academic research institutions, life science investors, and Evotec to develop novel medicines into commercial entities.
BiotechDeep TechSingapore, SG
BoardSteve Courtney(Expert in Residence)
Co-investorsClavystBioLeaps by Bayer
A pharmaceutical company that develops medicines and vaccines for patients globally.
BiotechHealthtechMedical DevicesCambridge, US
WYLIE W. VALE(Director)JOHN KNOPF(Executive Officer, Director)STEVEN ERTEL(Executive Officer)ROBERT STEININGER(Executive Officer)inKEVIN F. MCLAUGHLIN(Executive Officer)inMATTHEW L. SHERMAN(Executive Officer)
Co-investorsBessemer Venture PartnersForesite CapitalLowercarbon CapitalSofinnova VenturesVenrockCollaborative Fund
Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.
AI & Machine LearningBiotechDeep TechHealthtech
Jane Osbourn(Founder)Young Kwon(Founder)
Co-investorsRA CapitalSV Health InvestorsDCVC BioDementia Discovery FundOno Venture Investment, Inc.British Business Bank+3 more
Amber Therapeutics develops medical technology focused on treating mixed urinary incontinence, advancing toward pivotal clinical trials in the US with expanded feasibility studies in Europe.
Medical Devices
Co-investorsF-Prime CapitalIntuitive VenturesNew Enterprise Associates (NEA)Oxford Science Enterprises
Atsena Therapeutics is a clinical-stage gene therapy company developing treatments for inherited retinal diseases that cause vision loss.
BiotechDeep TechMedical DevicesAustin, US
Co-investorsWellington ManagementHatteras Venture PartnersSofinnova Ventures
Bird provides messaging infrastructure for developers, offering SMS, email, voice, and real-time messaging APIs built and operated end-to-end.
AI & Machine LearningCloud ComputingDeveloper ToolsEnterprise SoftwareSaaSAmsterdam, NL
Robert Vis(CEO)inBob Violier(Distinguished Engineer)inJoey van Ommen(Head of Product \u0026 Partner)inAdriaan Mol(Founder)in
Co-investorsAccelAnthem Venture Management, LlcAtomicoBlue LionBlue Lion GlobalGlynn Capital Management+14 more
Bonito develops encoded library and live-cell selection technologies to discover delivery ligands, generating high signal-to-noise data on membrane-bound targets to train AI models for precision drug delivery.
AI & Machine LearningBiotechDeep Tech
Richard Wagner(CEO, Cofounder)in
Co-investorsJAZZ Venture Partners
Cardiac Booster develops cardiac support technology for use in treating heart conditions.
BiotechHardwareHealthtechMedical DevicesGalway, IE
Florian Ludwig(CEO)inGerard Kilcommins(COO)Greg Mann(CFO)Patrick Griffin(VP Technology Development)inJeff Grainger(VP of Legal Affairs)Daragh Moloney(HR Director)in
Co-investorsAscension VenturesThuja Capital
Carrick Therapeutics is a biopharmaceutical company with a leadership team experienced in oncology drug development and commercialization.
BiotechDigital HealthHealthtechMedical DevicesBoston, US
Timothy Pearson(CEO)Ash Bahl(CSO)inJenny Horsfield(CBO)inStuart McIntosh(CMO)inDavid Sutherland(VP Finance & Controller)
Co-investorsARCH Venture PartnersB Capital GroupB4 CapitalCambridge Innovation CapitalGV (Google Ventures)Revelation Partners+2 more
.jpeg){kind=logo}
BiotechCambridge, US
Jill C. Milne(Executive Officer, Director)inIan Sanderson(Executive Officer)in
BoardRon Laufer(Director)Nicholas Galakatos(Director)inJean George(Director)Michael Ross(Director)
Co-investorsClarus Ventures
Catamaran Bio develops allogeneic CAR-NK cell therapies for cancer treatment, focusing on solid tumors, by combining natural killer (NK) cell biology with synthetic biology and non-viral cell engineering.
BiotechHealthtech
Branden Moriarity(Scientific Co-founder)Catherine Bollard(Scientific Co-founder)
Co-investorsAstellas Venture Management LLCSofinnova Partners
Cerevance develops precision novel therapeutics for central nervous system disorders, particularly neurodegenerative diseases, using its proprietary NETSseq platform and machine learning to identify targets from an extensive collection of human brain tissue samples.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesBoston, US
Craig Thompson(Chief Executive Officer)inSagar Vaidya(Chief Medical Officer)inCarrie Ann Cook(Chief Business Officer)Mark Carlton(Chief Scientific Officer)inOttavio V. Vitolo(Chief Medical Officer)in
Co-investorsDementia Discovery FundForesite CapitalGV (Google Ventures)SV Life SciencesDementia DiscoveryDolby Family Ventures+3 more
HealthtechSanta Rosa, US
Fred Khosravi(Director)Tony Fields(Executive Officer)
BoardJames Eadie(Director)Azin Parhizgar(Executive Officer, Director)inHenry A. Plain(Director)Leo Nelson Hopkins(Director)
Co-investors415 CapitalEaston CapitalMorgenthalerSante Ventures
CoolSculpting offers FDA-cleared body-contouring procedures that use controlled cooling to reduce visible fat bulges in areas such as the chin, abdomen, thighs, and flanks, along with the CoolTone device for muscle strengthening and toning.
HealthtechMedical DevicesWellness & Fitness
Co-investorsAisling Capital
Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid.
BiotechHealthtechMedical DevicesSan Diego, US
James Mackay(President & Chief Executive Officer)inNihar Bhakta(Chief Medical Officer)inAshwin Ram(Chief Operating Officer)inDeAnne Reid(Chief Administrative Officer)in
Co-investorsCatalys PacificNovo HoldingsAN Venture PartnersFrazier Life SciencesLongwood Fund
Curie.Bio is a biotech venture firm pairing seed capital with in-house drug discovery support for therapeutics founders.
Zach Weinberg(Founder)inAlexis Borisy(Founder)Christoph Lengauer(Founder)
Co-investorsAlleyCorpARCH Venture PartnersBoxGroupDNA CapitalF-Prime CapitalGV (Google Ventures)+5 more
Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.
BiotechHealthtechCambridge, US
Kevin Mills(Executive Officer, Director)inRonald Goldstein(Executive Officer)inDonald Corcoran(Executive Officer, Director)inMarkus Renschler(Director)in
BoardTimothy Romberger(Director)Barry Mills(Director)
Co-investorsDroia VenturesOUP (Osage University Partners)Shah Family OfficeAlly Bridge GroupDe Novo VenturesJanus Henderson Investors+3 more
Earlens makes a hearing aid that vibrates the eardrum directly rather than using speakers to amplify sound, allowing amplification across a broad audible frequency range including higher frequencies for speech understanding.
HardwareHealthtechMedical DevicesMenlo Park, US
Rodney Perkins, M.D.(Director)William M. Facteau(Executive Officer, Director)Bernard Shay(Executive Officer)Phil Lyons(Executive Officer)Brent Edwards(Executive Officer)Greg Koskowich(Executive Officer)
Co-investorsAisling CapitalNew Enterprise Associates (NEA)Windham Capital PartnersMorgenthalerSightLine Partners
EndoGastric Solutions offers the Transoral Incisionless Fundoplication (TIF 2.0) procedure and the EsophyX device used to treat GERD, along with reimbursement and technical/administrative support (TAP program) for medical practices.
BiotechHealthtechMedical DevicesSan Mateo, US
Philip Macdonald(Executive Officer)Louis Baldino(Executive Officer, Director)Lilip Lau(Executive Officer)Josh DeFonzo(Executive Officer)in
BoardMichael Carusi(Director)inArda Minocherhomjee(Director)
Co-investorsAccelmed PartnersCanaan PartnersEvidity Health CapitalVCFA GroupAdvanced Technology VenturesDe Novo Ventures+2 more
FIRE1 develops NORM, an implantable sensor placed in the inferior vena cava to directly measure fluid volume in heart failure patients, paired with a self-management platform to help patients engage with their own care.
Digital HealthHardwareMedical DevicesDublin, IE
Co-investorsAndera PartnersGimvIreland Strategic Investment FundLongitude CapitalNew Enterprise Associates (NEA)Seventure Partners+5 more
Flex Pharma provides accessible generic vasodilator medications, including PDE5 inhibitors, to U.S. patients at lower costs than brand-name alternatives.
BiotechDigital HealthHealthtechMedical Devices
Dr. Rod MacKinnon(Founder)
Co-investorsBessemer Venture PartnersEcoR1 CapitalLongwood Fund
Precision medicine company developing therapeutics for genetically-defined age-related macular degeneration.
BiotechCambridge, US
James McLaughlin(Executive Officer, Director)in
BoardJean George(Director)Jason Rhodes(Director)inCarl Gordon(Director)in
Co-investorsAltium CapitalAtlas VentureOrbiMed
Hydra provides analytics query execution for Postgres databases with separated compute resources, automatic scaling, and built-in caching, designed for time series and event data workloads across multiple deployment environments.
Data & InfrastructureDeveloper ToolsEnterprise SoftwareSan Francisco, US
Joseph Sciarrino(Founder)inJD Dance
Co-investorsY Combinator10X Capital10x FoundersAntlerComcast VenturesEra Funds+12 more
BiotechCambridge, US
Magdalene Moran, Ph.D.(Executive Officer)Bert Chenard, Ph.D.(Executive Officer)Russell Herndon(Executive Officer, Director)Tom Burke(Executive Officer)
BoardVincent Miles(Director)Jean George(Director)
Co-investorsNew Enterprise Associates (NEA)Saints CapitalAbingworthLilly Ventures
Medisix Therapeutics develops a pipeline of therapeutic products using integrated technology platforms spanning the product lifecycle, supported by a CMC platform for large-scale manufacturing.
BiotechHealthtechSingapore, SG
Professor Dario Campana, MD, PhD(Scientific Founder)Andrew Bruce, BSc(Chief Executive Officer)
Day One (part of Servier) is a biopharmaceutical company developing targeted oncology medicines, with a focus on cancers affecting patients of all ages, including pediatric low-grade glioma (pLGG).
BiotechHealthtechCambridge, US
MICHAEL J. KAUFMAN(Executive Officer)inDonald Bergstrom(Executive Officer)inANNA PROTOPAPAS(Executive Officer, Director)Timothy Lowinger(Executive Officer)Eva Jack(Executive Officer)Wayne Foster(Executive Officer)
Co-investorsBain Capital Life SciencesF-Prime CapitalNew Enterprise Associates (NEA)Nextech InvestPfizer Venture InvestmentsRho Ventures+3 more
Terumo Neuro (formerly MicroVention) develops minimally invasive catheter-based medical devices for treating neurovascular disorders including cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations.
Enterprise SoftwareHealthtechMedical DevicesAliso Viejo, US
Carsten Schroeder(President and CEO)in
HealthtechFremont, US
Anton Clifford(Executive Officer)inJames Leech(Executive Officer)inChristopher Gleason(Executive Officer)inKevin K. Sidow(Executive Officer, Director)
BoardJoshua Makower(Director)Shahzad Malik(Director)in
Co-investorsNew Enterprise Associates (NEA)Runway Growth CapitalAdvent Life SciencesGBS Venture Partners Ltd.Gilde HealthcareMorgenthaler+1 more
Nimbus Therapeutics is a biotechnology company that designs precision small molecule medicines using a computational, multidisciplinary drug discovery approach.
AI & Machine LearningBiotechDeep TechHealthtech
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesDementia Discovery FundGV (Google Ventures)Pfizer Venture Investments+4 more
Portola develops research and investigates new targets, modalities, and technologies to address rare disease challenges for patients and their families.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsBluebird VenturesFrazier Life SciencesProspect Venture PartnersKhosla VenturesNFDG
ProVerum is a venture-backed medical device startup developing minimally invasive technologies to treat benign prostatic hyperplasia (BPH).
HardwareHealthtechMedical DevicesDublin, IE
Dr Conor Harkin(Founder)inRíona Ní Ghriallais(Founder)in
Co-investorsAtlantic Bridge VenturesIreland Strategic Investment FundMVM Life Science PartnersOrbiMed
UCB is a global biopharmaceutical company that develops medicines and treatment-support services for people living with neurological and autoimmune conditions, including rare diseases such as epilepsy.
BiotechHealthtechCambridge, US
Douglas A. Treco(Executive Officer, Director)Kerry Black(Executive Officer)in
BoardEdward Mathers(Director)Rajeev Shah(Director)inPeter Bisgaard(Director)Jason Lettman(Director)
Co-investorsNew Enterprise Associates (NEA)RA CapitalMorgenthaler
Relievant offers the Intracept Procedure, a minimally invasive, FDA-cleared medical intervention designed to relieve chronic low back pain caused by vertebrogenic pain.
Medical DevicesRedwood City, US
Alex DiNello(Executive Officer, Director)
BoardRichard Mott(Director)Justin Klein(Director)inBrent Ahrens(Director)inJason Lettman(Director)John Ryan(Director)
Co-investorsCanaan PartnersEmergent Medical Partners, LLPNew Enterprise Associates (NEA)MorgenthalerVensana Capital
Co-investorsLifeforce CapitalPfizer Venture InvestmentsDigitalis VenturesMorgenthalerRoche Venture FundSR One Capital Management
SetPoint Medical develops an FDA-approved implantable neurostimulation device that stimulates the vagus nerve to reduce inflammation, offering a device-based treatment for adults with moderate-to-severe rheumatoid arthritis who have not responded to biologic or targeted synthetic drugs.
BiotechHealthtechMedical DevicesValencia, US
Murthy Simhambhatla(CEO)inDavid Chernoff(Chief Medical Officer (MD))Yaakov Levine(PhD)inRohan Seth(Executive Officer)inKevin Tracey(Founder)
Co-investorsAlly Bridge GroupNew Enterprise Associates (NEA)Norwest Venture PartnersTopspin PartnersAsahi Kasei Corporate Venture CapitalCatalio Capital Management, LP+8 more
Tagworks Pharmaceuticals develops cancer therapies using its Click-to-Release platform, a chemical reaction that activates antibody-drug conjugates (ADCs), masked immunomodulators, and other prodrugs on-target while deactivating radioimmunotherapies off-target.
BiotechHealthtechMedical DevicesNijmegen, NL
Co-investorsBifNew Enterprise Associates (NEA)Novartis Venture FundYsios CapitalClarus VenturesGilde Healthcare+1 more
Tallac Therapeutics is a clinical-stage biopharmaceutical company developing oligonucleotide-based antibody conjugates (TRAAC candidates) designed to deliver immune-activating agents to tumor microenvironments for oncology indications.
BiotechHealthtechMedical DevicesBurlingame, US
Hong Wan(Executive Officer, Director)in
BoardRan Geng(Director)Michael Carusi(Director)Isaac Cheng(Director)Christine Brennan(Director)Corey Goodman(Director)in
Co-investorsMRL Ventures FundvenBio PartnersMatrix Partners ChinavenBio Global Strategic
The Foundry is a medical device incubator that identifies unmet clinical needs and builds companies around new technologies to address them, working with physician collaborators to develop products from concept to market.
BiotechDeep TechHealthtechMedical Devices
Co-investorsNew Enterprise Associates (NEA)Oasis Capital
Tizona Therapeutics is a biotechnology company developing first-in-class immuno-oncology therapeutics, including its lead clinical-stage asset TTX-080, aimed at changing cancer progression and relapse.
AI & Machine LearningBiotechHealthtech
Vijay K. Kuchroo(Scientific Co-Founder & Advisory Board Member)Drew Pardoll(Scientific Co-Founder & Advisory Board Member)Dario Vignali(Scientific Co-Founder & Advisory Board Member)Jedd Wolchok(Scientific Co-Founder & Advisory Board Member)Christine O'Brien(Chief Executive Officer & Board Member)inCourtney Beers(Chief Scientific Officer)
Co-investorsCanaan PartnersMPM BioImpactAbingworthGilead SciencesAstellas Venture Management LLC
Transcend Medical was a Menlo Park, CA medical-device company spun out of ForSight Labs that developed the CyPass Micro-Stent, a minimally invasive glaucoma implant to reduce intraocular pressure.
Menlo Park, US
Co-investorsCanaan PartnersLatterell Venture Partners
Trishula Therapeutics is a clinical-stage biopharmaceutical company developing TTX-030, a first-in-class anti-CD39 antibody for advanced cancers.
BiotechHealthtech
Anil Singhal(President and CEO)inSiddhartha Mitra(Chief Medical Officer)in
Co-investorsCanaan PartnersMPM BioImpactAstellas Venture Management LLC
San Diego biotech founded in 2019 developing oral anti-inflammatory small molecules targeting RNA binding proteins.
Co-investorsARCH Venture PartnersMedical Excellence CapitalCanaan Partners
Urotronic develops drug-coated balloons for interventional urology, including the Optilume products for treating benign prostatic hyperplasia (BPH) and urethral strictures.
HealthtechMedical DevicesPlymouth, US
Junfeng Wang(Director)David Perry(Executive Officer, Director)Tan Ching(Director)Hui Hu(Director, Promoter)Lixiao Wang(Director, Promoter)Doug Kohrs(Director)
Co-investorsHM Venture PartnersEnterprise IrelandGilde HealthcareIreland Strategic Investment FundLegend CapitalMVM Life Science Partners+1 more
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Ivana Magovcevic-Liebisch(Executive Officer, Director)Christopher Verni(Executive Officer)inMary Thistle(Director)Evan Thackaberry(Executive Officer)Suzanne Bruhn(Director)Gerhard Koenig(Director)
Co-investorsAtlas VenturePivotal Life SciencesVida VenturesHatteras Venture PartnersLongwood Fund
Willow (originally founded as Contento) offers social media management for small and medium-sized B2B professional service providers, combining a scheduling and content platform with AI tools and human social media coaching.
AI & Machine LearningEnterprise SoftwareMarketing TechSaaSGhent, BE
Ludwig Dumont(Founder)in
Co-investorsPMVSmartFinHetz VenturesMeritech Capital PartnersNew Enterprise Associates (NEA)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Catalyst Biosciences Inc.Hat Trick MedicalKona MedicalMediSix TherapeuticsMiramar LabsArdianAtsena TherapeuticsCabochon AestheticsCrystalys TherapeuticsDisarm TherapeuticsDisarmtxElcelyx TherapeuticsFive Prime Therapeuticsfive-prime-bgForSight VISION4ForSight VISION5HypnionLwwOnyxPlexxikonProteolixSciodermWillow PumpZELTIQ
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 11
3 IPOs · 8 acquisitions · showing 8Alx OncologyNASDAQ: ALXOShoulder InnovationsNYSE: SIVerastemNASDAQ: VSTMGynesonicsacq. by HologicFive Prime Therapeuticsacq. by AmgenPortola Pharmaceuticalsacq. by AlexionProteolixacq. by Onyx PharmaceuticalsVigil Neuroscienceacq. by Sanofi
Portfolio news
latest coverage across their companiesAlchemab · trysignalbase.com · Jul 10, 2026
Shoulder Innovations · prnewswire.com · May 13, 2026
PsiThera · finsmes.com · Dec 16, 2025
ProVerum · eu-startups.com · Aug 26, 2025
Reprieve Cardiovascular · finance.yahoo.com · Aug 14, 2025
Allay Therapeutics · finsmes.com · Jun 5, 2025
IPO stake values · per SEC filings · 2
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Alx Oncology | 12.0% | $76.00 | Dec 2020 | $358.8M |
| Shoulder Innovations | 8.0% | $15.00 | Aug 2025 | $24.3M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has Lightstone Ventures made?
- Lightstone Ventures has 87 tracked investments, 11 of which have exited, including 8 dated in the last 24 months.
- What stage does Lightstone Ventures invest at?
- Lightstone Ventures invests at the Pre-Seed, Seed, Series A, Series B, Series C stages.
- What sectors does Lightstone Ventures focus on?
- Lightstone Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Lightstone Ventures located?
- Lightstone Ventures is headquartered in Portola Valley, US.
- Does Lightstone Ventures lead rounds?
- Yes, Lightstone Ventures leads investment rounds.
- Who does Lightstone Ventures co-invest with?
- Lightstone Ventures most often shares deals with New Enterprise Associates (NEA), Canaan Partners, GV (Google Ventures), among 148 tracked co-investors.
- What size deals does Lightstone Ventures back?
- Across 12 deals with disclosed amounts, Lightstone Ventures has joined rounds of $20M – $120M (median $56.5M).
Co-investors · 19
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Morgenthaler is a venture capital and private equity firm that has focused on building valuable companies for over 40 years.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.
Arboretum Ventures is a Midwest-based venture capital firm focused on the healthcare industry, investing in early-stage companies across medical devices, life science tools and diagnostics, tech-enabled care delivery, and pharma adjacencies.
SV Health Investors is a global private equity and venture capital platform dedicated to healthcare, running specialized funds across biotechnology (including dementia), healthcare growth equity, and medtech.
SR One Capital Management is a life sciences venture capital firm that takes a 'back-and-build' approach, providing entrepreneurs with human, intellectual, and financial resources. It emerged from the legacy SR One team formerly part of GSK.
Santé is a healthcare-focused investment firm that manages over $1 billion across venture and public-market strategies. Through Santé Ventures it backs private healthcare startups, and through Santé Capital it runs a liquid hedge fund strategy using proprietary data-science software.
Clarus Ventures is a life sciences investment firm, now part of Blackstone Life Sciences (BXLS), that funds drug development, including late-stage Phase III programs. Based in Menlo Park, California, its team has been involved in bringing numerous medicines to market across pharmaceutical and biotechnology companies.
JAZZ Venture Partners is a venture capital firm investing in early- and growth-stage companies at the intersection of technology, science, and human performance across enterprise, wellness, healthcare, and consumer markets.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
▶7 more co-investors
Johnson & Johnson Innovation – JJDCNovartis Venture FundRoche Venture FundSamsara BioCapitalThe Column GroupOptum VenturesNew Leaf Venture Partners
Firms observed investing alongside Lightstone Ventures, from public investor directories. Shared companies are the overlap with Lightstone Ventures's recorded portfolio.
Similar investors
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
MDI Ventures is the corporate venture capital arm of Indonesian telecommunications company Telkom Indonesia, investing in high-growth technology startups across Southeast Asia and globally, with a focus on creating synergies between portfolio companies and Telkom Group and Indonesian state-owned enterprises.